British Columbia Cancer Agency Agrees to Fund Genomic Health's Oncotype DX | GenomeWeb

NEW YORK (GenomeWeb) ─ The British Columbia Cancer Agency has agreed to reimburse for Genomic Health's Oncotype DX breast cancer recurrence test.

The multi-gene expression diagnostic is available in four other Canadian provinces in addition to British Columbia, including Ontario, Quebec, Saskatchewan, and Newfoundland.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.